Search
Collegium Pharmaceutical Inc
COLLAdd to Watchlist
22.770USD
+0.390+1.74%
Close 09-18 16:00（ET）
741.61MMarket Cap
9.68P/E TTM
Collegium Pharmaceutical Inc (COLL) Revenue Performance
Updated: Jun 30, 2026Last year, Collegium Pharmaceutical Inc generated 336.96M USD for its biggest-performing segment, Nucynta IR. The United States made the largest contribution, accounting for 780.57M USD last year. For the latest quarter, Collegium Pharmaceutical Inc reported the revenue of 212.79M USD for the period ending 2026-06-30, which came from the top-performing segment, Azstarys. United States contributed the highest revenue, at 199.88M USD.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Nucynta IR
Belbuca
Xtampza ER
Jomay PM
Nucynta ER
Symproic
Other
Nucynta
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Nucynta IR
336.96M(33.62%)
312.01M(37.02%)
290.25M(38.76%)
112.06M(24.15%)
--(--)
--(--)
--(--)
--(--)
Belbuca
221.65M(22.12%)
211.27M(25.07%)
182.09M(24.32%)
126.46M(27.26%)
--(--)
--(--)
--(--)
--(--)
Xtampza ER
199.31M(19.89%)
191.33M(22.70%)
177.37M(23.69%)
138.80M(29.92%)
103.71M(37.46%)
127.98M(41.28%)
105.01M(35.39%)
69.38M(24.74%)
Jomay PM
148.86M(14.85%)
37.24M(4.42%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Nucynta ER
80.98M(8.08%)
75.77M(8.99%)
82.65M(11.04%)
72.42M(15.61%)
--(--)
--(--)
--(--)
--(--)
Symproic
14.45M(1.44%)
15.10M(1.79%)
16.50M(2.20%)
12.27M(2.64%)
--(--)
--(--)
--(--)
--(--)
Other
--(--)
--(--)
--(--)
1.93M(0.41%)
--(--)
--(--)
--(--)
--(--)
Nucynta
--(--)
--(--)
--(--)
--(--)
173.16M(62.54%)
182.03M(58.72%)
191.69M(64.61%)
211.03M(75.26%)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
FY2025
United States
780.57M(100.00%)